TY - JOUR
T1 - Effect of a multicomponent intervention on achievement and improvements in quality-of-care indices among people with Type 2 diabetes in South Asia
T2 - the CARRS trial
AU - Shah, M. K.
AU - Kondal, D.
AU - Patel, S. A.
AU - Singh, K.
AU - Devarajan, R.
AU - Shivashankar, R.
AU - Ajay, V. S.
AU - Menon, V. U.
AU - Varthakavi, P. K.
AU - Viswanathan, V.
AU - Dharmalingam, M.
AU - Bantwal, G.
AU - Sahay, R. K.
AU - Masood, M. Q.
AU - Khadgawat, R.
AU - Desai, A.
AU - Prabhakaran, D.
AU - Narayan, K. M.V.
AU - Tandon, N.
AU - Ali, M. K.
N1 - Funding Information:
The institutional ethics committees at each participating site and the coordinating centres (Public Health Foundation of India, New Delhi, India, and Emory University, Atlanta, Georgia) approved the trial.
Funding Information:
The CARRS trial was funded in part by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services, under contract number HHSN268200900026C, and by the UnitedHealth Group, Minneapolis, MN, USA. Several members of the research team at the Public Health Foundation of India and Emory University were supported by the Fogarty International Clinical Research Scholars and Fellows programme through grant number 5R24TW007988 from the National Institutes of Health, THE Fogarty International Centre through Vanderbilt University, the Emory Global Health Institute, and the D43 NCDs in India Training Program through award number 1D43HD05249 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and Fogarty International Centre. K.S. was supported by the Fogarty International Centre, National Institutes of Health, under award number D43TW008332 (ASCEND Research Network). M.K.A. and S.A.P. were supported by the National Institute of Mental Health supplemental grant under award number: R01MH100390‐04S1. M.K.S. is supported in part by the National Centre for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378 and KL2TR002381.
Funding Information:
The CARRS trial was funded in part by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services, under contract number HHSN268200900026C, and by the UnitedHealth Group, Minneapolis, MN, USA. Several members of the research team at the Public Health Foundation of India and Emory University were supported by the Fogarty International Clinical Research Scholars and Fellows programme through grant number 5R24TW007988 from the National Institutes of Health, THE Fogarty International Centre through Vanderbilt University, the Emory Global Health Institute, and the D43 NCDs in India Training Program through award number 1D43HD05249 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and Fogarty International Centre. K.S. was supported by the Fogarty International Centre, National Institutes of Health, under award number D43TW008332 (ASCEND Research Network). M.K.A. and S.A.P. were supported by the National Institute of Mental Health supplemental grant under award number: R01MH100390-04S1.?M.K.S. is supported in part by the National Centre for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378 and KL2TR002381.
Publisher Copyright:
© 2019 Diabetes UK
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Aims: To evaluate whether and what combinations of diabetes quality metrics were achieved in a multicentre trial in South Asia evaluating a multicomponent quality improvement intervention that included non-physician care coordinators to promote adherence and clinical decision-support software to enhance physician practices, in comparision with usual care. Methods: Using data from the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS) trial, we evaluated the proportions of trial participants achieving specific and combinations of five diabetes care targets (HbA1c<53 mmol/mol [7%], blood pressure <130/80 mmHg, LDL cholesterol <2.6 mmol/L, non-smoking status, and aspirin use). Additionally, we examined the proportions of participants achieving the following risk factor improvements from baseline: ≥11-mmol/mol (1%) reduction in HbA1c, ≥10-mmHg reduction in systolic blood pressure, and/or ≥0.26-mmol/l reduction in LDL cholesterol. Results: Baseline characteristics were similar in the intervention and usual care arms. Overall, 12.3%, 29.4%, 36.5%, 19.5% and 2.2% of participants in the intervention group and 16.2%, 38.3%, 31.6%, 11.3% and 0.8% of participants in the usual care group achieved any one, two, three, four or five targets, respectively. We noted sizeable improvements in HbA1c, blood pressure and cholesterol, and found that participants in the intervention group were twice as likely to achieve improvements in all three indices at 12 months that were sustained over 28 months of the study [relative risk 2.1 (95% CI 1.5,2.8) and 1.8 (95% CI 1.5,2.3), respectively]. Conclusions: The intervention was associated with significantly higher achievement of and greater improvements in composite diabetes quality care goals. However, among these higher-risk participants, very small proportions achieved the complete group of targets, which suggests that achievement of multiple quality-of-care goals is challenging and that other methods may be needed in closing care gaps.
AB - Aims: To evaluate whether and what combinations of diabetes quality metrics were achieved in a multicentre trial in South Asia evaluating a multicomponent quality improvement intervention that included non-physician care coordinators to promote adherence and clinical decision-support software to enhance physician practices, in comparision with usual care. Methods: Using data from the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS) trial, we evaluated the proportions of trial participants achieving specific and combinations of five diabetes care targets (HbA1c<53 mmol/mol [7%], blood pressure <130/80 mmHg, LDL cholesterol <2.6 mmol/L, non-smoking status, and aspirin use). Additionally, we examined the proportions of participants achieving the following risk factor improvements from baseline: ≥11-mmol/mol (1%) reduction in HbA1c, ≥10-mmHg reduction in systolic blood pressure, and/or ≥0.26-mmol/l reduction in LDL cholesterol. Results: Baseline characteristics were similar in the intervention and usual care arms. Overall, 12.3%, 29.4%, 36.5%, 19.5% and 2.2% of participants in the intervention group and 16.2%, 38.3%, 31.6%, 11.3% and 0.8% of participants in the usual care group achieved any one, two, three, four or five targets, respectively. We noted sizeable improvements in HbA1c, blood pressure and cholesterol, and found that participants in the intervention group were twice as likely to achieve improvements in all three indices at 12 months that were sustained over 28 months of the study [relative risk 2.1 (95% CI 1.5,2.8) and 1.8 (95% CI 1.5,2.3), respectively]. Conclusions: The intervention was associated with significantly higher achievement of and greater improvements in composite diabetes quality care goals. However, among these higher-risk participants, very small proportions achieved the complete group of targets, which suggests that achievement of multiple quality-of-care goals is challenging and that other methods may be needed in closing care gaps.
UR - http://www.scopus.com/inward/record.url?scp=85074574000&partnerID=8YFLogxK
U2 - 10.1111/dme.14124
DO - 10.1111/dme.14124
M3 - Article
C2 - 31479537
AN - SCOPUS:85074574000
SN - 0742-3071
VL - 37
SP - 1825
EP - 1831
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 11
ER -